Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT

Iodine Density of Lymphoma, Metastatic SCCA, and... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/13-498" }, "headline": "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based...", "datePublished": "2024-05-17T13:04:58", "dateModified": "2025-01-02T16:34:08", "author": [ { "@type": "Person", "name": "Varalee Mingkwansook" }, { "@type": "Person", "name": "Urusaya Wangprasertkul" }, { "@type": "Person", "name": "Warit Tarathipmon" }, { "@type": "Person", "name": "Arvemas Watcharakorn" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Objective To compare iodine density (ID) and contrast-enhanced attenuation value (CEAV) from dual-layer spectral computed tomography (DLSCT) scans of lymphomatous, metastatic squamous cell carcinoma (SCCA), and normal cervical lymph nodes. Methods Data including ID and CEAV were retrospectively collected from patients who underwent DLSCT of the neck between January 2020 and August 2023. Results from each group (lymphomatous, metastatic SCCA, and normal) were compared and analyzed using one-way ANOVA and receiver operating characteristic curve. Results 129 cervical lymph nodes were collected from patients who met the inclusion criteria (50, 41, and 38 nodes from the lymphomatous, metastatic SCCA, and normal group, respectively). The mean ID of lymphomatous, metastatic SCCA, and normal nodes was 1.01±0.27, 1.36±0.28, and 1.45±0.29 mg/mL, respectively. Comparing lymphomatous nodes with metastatic SCCA nodes, the lymphomatous nodes had significantly lower values of ID (p<0.002) and CEAV (p<0.001). Similarly, when comparing lymphomatous nodes with normal nodes, the lymphomatous nodes had significantly lower values of ID (p<0.001) and CEAV (p<0.001). The optimal ID cut-off value for distinguishing between lymphomatous and metastatic SCCA nodes was 1.175 mg/ml (specificity of 84.2%, sensitivity 77.8%, AUC 0.788, P = 0.003). The optimal CEAV cut-off value was 77.5 HU (specificity 88.9%, sensitivity 78.9%, AUC 0.851, P<0.001). Conclusions The ID and CEAV measurements from DLSCT were significantly different between lymphomatous, metastatic SCCA, and normal lymph nodes. These findings indicate that DLSCT can be used to distinguish between these conditions in the diagnosis of cervical lymph nodes. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/13-498", "name": "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph..." } } ] } Home Browse Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Mingkwansook V, Wangprasertkul U, Tarathipmon W and Watcharakorn A. Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.12688/f1000research.146149.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Revised Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] Previous title: Iodine density of lymphoma, metastatic SCCA, and normal cervical lymph nodes: Based on DLSCT Varalee Mingkwansook https://orcid.org/0000-0002-1358-678X 1 , Urusaya Wangprasertkul 1 , Warit Tarathipmon 1 , Arvemas Watcharakorn 1 Varalee Mingkwansook https://orcid.org/0000-0002-1358-678X 1 , Urusaya Wangprasertkul 1 , Warit Tarathipmon 1 , Arvemas Watcharakorn 1 PUBLISHED 02 Jan 2025 Author details Author details 1 Radiology, Thammasat University, meung, pathumtani, 12000, Thailand Varalee Mingkwansook Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Urusaya Wangprasertkul Roles: Data Curation, Project Administration Warit Tarathipmon Roles: Formal Analysis Arvemas Watcharakorn Roles: Methodology OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Faculty of Medicine – Thammasat University collection. Abstract Objective To compare iodine density (ID) and contrast-enhanced attenuation value (CEAV) from dual-layer spectral computed tomography (DLSCT) scans of lymphomatous, metastatic squamous cell carcinoma (SCCA), and normal cervical lymph nodes. Methods Data including ID and CEAV were retrospectively collected from patients who underwent DLSCT of the neck between January 2020 and August 2023. Results from each group (lymphomatous, metastatic SCCA, and normal) were compared and analyzed using one-way ANOVA and receiver operating characteristic curve. Results 129 cervical lymph nodes were collected from patients who met the inclusion criteria (50, 41, and 38 nodes from the lymphomatous, metastatic SCCA, and normal group, respectively). The mean ID of lymphomatous, metastatic SCCA, and normal nodes was 1.01±0.27, 1.36±0.28, and 1.45±0.29 mg/mL, respectively. Comparing lymphomatous nodes with metastatic SCCA nodes, the lymphomatous nodes had significantly lower values of ID (p<0.002) and CEAV (p<0.001). Similarly, when comparing lymphomatous nodes with normal nodes, the lymphomatous nodes had significantly lower values of ID (p<0.001) and CEAV (p<0.001). The optimal ID cut-off value for distinguishing between lymphomatous and metastatic SCCA nodes was 1.175 mg/ml (specificity of 84.2%, sensitivity 77.8%, AUC 0.788, P = 0.003). The optimal CEAV cut-off value was 77.5 HU (specificity 88.9%, sensitivity 78.9%, AUC 0.851, P< 0.001). Conclusions The ID and CEAV measurements from DLSCT were significantly different between lymphomatous, metastatic SCCA, and normal lymph nodes. These findings indicate that DLSCT can be used to distinguish between these conditions in the diagnosis of cervical lymph nodes. READ ALL READ LESS Keywords Iodine density, contrast-enhanced attenuation value, cervical lymph node, lymphoma, squamous cell cancer, dual-layer spectral computed tomography Corresponding Author(s) Varalee Mingkwansook ( [email protected] ) Close Corresponding author: Varalee Mingkwansook Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 Mingkwansook V et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Mingkwansook V, Wangprasertkul U, Tarathipmon W and Watcharakorn A. Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.12688/f1000research.146149.2 ) First published: 17 May 2024, 13 :498 ( https://doi.org/10.12688/f1000research.146149.1 ) Latest published: 02 Jan 2025, 13 :498 ( https://doi.org/10.12688/f1000research.146149.2 ) Revised Amendments from Version 1 - The phrase 'A Comparative Analysis' was incorporated into the title following the recommendation. - Detailed information regarding the ROI placement was included in the methods section. - The topic of inter-reader variability was addressed in the discussion section. - The phrase 'A Comparative Analysis' was incorporated into the title following the recommendation. - Detailed information regarding the ROI placement was included in the methods section. - The topic of inter-reader variability was addressed in the discussion section. See the authors' detailed response to the review by Siriwan Piyapittayanan See the authors' detailed response to the review by Jarunee Intrapiromkul READ REVIEWER RESPONSES Background Cervical lymphadenopathy is a common problem, and the malignancy rate of lymph nodes in the neck exceeds 50%. 1 – 5 The most prevalent etiologies in adults are lymphoma and metastatic squamous cell carcinoma (SCCA). 2 These conditions may present with enlarged cervical nodes and upper aerodigestive tract masses which might overlap and be misdiagnosed on a conventional CT 6 – 8 Dual-layer spectral CT (DLSCT), a subgroup of dual-energy CT (DECT), can generate additional data, including iodine density (ID). 9 , 10 This study compares ID and contrast-enhanced attenuation value (CEAV) between lymphomatous, metastatic SCCA, and normal cervical lymph node groups. Methods Study population The study was approved by the Human Research Ethics Committee of Thammasat University (Medicine) (ref. No. MTU-EC-RA-0-222/66). Patients who underwent DLSCT of the neck with iodinated contrast media between Jan 2020 and Aug 2023 at Thammasat Hospital were retrospectively examined. The inclusion criteria for each group were 1) Metastatic SCCA patients who had primary SCCA of head and neck with pathologically proven metastatic nodes and pre-treatment DLSCT of neck, 2) Lymphoma patients with a final diagnosis of lymphoma involving a neck node with pre-treatment DLSCT of the neck, 3) Normal node patients with DLSCT of the neck for any reason except malignancy, lymphoma, and inflammatory disease. The exclusion criteria were 1) Patients with coexisting primary malignancies (head and neck or another region), and 2) Patients with suboptimal DLSCT, e.g., severe motion or metallic artifact. Imaging acquisition A dual-layer spectral CT scanner, DLSCT (Spectral CT7500 and Philips IQon Spectral CT, Philips Healthcare, Eindhoven, Netherlands), was used to scan all patients using the same standard CT neck protocol of the institute. CT parameters were as follows: 1.4:1 helical pitch, 0.4-second rotation time, and 120 kVp tube voltage with a reconstructed FOV of 512 mm2. Automated mAS and beam collimation were registered and differed depending on body habitus. The detector configurations were 128×0.625 mm for Spectral CT7500 and 64×0.625 mm for Philips IQon Spectral CT. CT neck was performed along the skull base to the aortic arch in the craniocaudal fashion. Intravenous injection of non-ionic iodinated contrast agent (Ultravist 300 mg/ml, Bayer Vital GmbH, Leverkusen, Germany, catalogue numbers: 064-18-27492-00) with 30-mL saline chaser (0.9% sodium chloride, Thai Nakorn Patana, Nonthaburi, Thailand, catalogue numbers: F-013-13035) was administered at the rate of 2.5 mL/sec using a dual syringe injection system (Stellant, MEDRAD, Indianola, Pennsylvania). The non-ionic iodinated contrast agent dosage varied according to body weight (1.5 mL/kg). Enhanced images were obtained 70 seconds after contrast agent injection. Imaging post-processing Spectral post-processing workstation (IntelliSpace Portal v11, Philips Healthcare, Netherlands) was used togenerateID and contrast-enhanced images ( Figures 1 , 2 , and 3 ). Figure 1. Measurement of ID and CEAV in lymphomatous node. An Axial CT image of a patient with lymphoma shows CEAV measurement (70.9 HU) of the enlarged lymph node at left cervical level IIA (A). An ID measurement (1.14 mg/ml) of this lymph node at the same CT level (B). Figure 2. Measurement of ID and CEAV in metastatic SCCA node. An Axial CT image of a patient with SCCA at gum shows CEAV measurement (110.4 HU) of the enlarged lymph node at left cervical level IB (A). An ID measurement (2.23 mg/ml) of this lymph node at the same CT level (B). Figure 3. Measurement of ID and CEAV in normal node. An Axial CT image of a patient with normal lymph nodes shows CEAV measurement (80.5 HU) of a right cervical level IB node (A). An ID measurement (1.41 mg/ml) of this lymph node at the same CT level (B). Image assessment ID and CEAV were measured by placing rounded or oval-shaped regions of interest (ROI) on axial images in which lymph nodes appeared the largest ( Figures 1 , 2 , and 3 ). Regions of interest (ROIs) for each lymph node were delineated to encompass the largest possible area within the solid portion of the node, ensuring that each ROI had a minimum size of 6 mm 2 . Areas of necrosis, cysts, calcifications, and fat were systematically excluded from the ROI placement. In instances where the solid portion exhibited heterogeneous enhancement, the largest feasible ROI was selected to ensure accurate and reliable measurements. The mean Hounsfield unit (HU) of each ROI was used as the representative value for the lymph node. ROIs were placed on axial images where the lymph nodes displayed the most prominent enhancement, with a maximum of three nodes selected for analysis. When the lymph node showed consistent enhancement across multiple slices, the slice displaying the largest cross-sectional area was chosen to obtain the most representative ROI. All lymph nodes were evaluated by a radiologist with 15 years of experience in head and neck imaging. The average ID and CEAV values of each patient were recorded. The selected lymphomatous and metastatic SCCA nodes had to be enlarged (>8 mm in the short axis) or have other radiologic characteristics of pathologic nodes. To achieve reliable ROI, normal nodes had to be 5 mm in the short axis without other radiologic signs of pathologic nodes. ID and CEAV of the sternocleidomastoid muscle (SCM) and internal jugular vein (IJV) were obtained from every patient using circular or ellipsoid ROIs. Standard of reference Lymphomatous nodes were selected from patients with histopathologically proven lymphoma from cervical nodes or other head and neck areas. The selected lymphomatous nodes showed evidence of post-treatment regression on follow-up imaging. Metastatic SCCA nodes selected on CT had to correlate with the operative report and pathological results regarding side, nodal station, and size. Normal cervical lymph nodes were included in patients who were free from malignancy or inflammation in the neck. Statistics ID and CEAV were interpreted in terms of mean, standard deviation (SD), median, and interquartile range (IQR). One-way ANOVA was used to compare mean ID and CEAV between the 3 groups. ROC curve was used to estimate the area under the curve (AUC) with 95%CI for differential diagnosis between lymphomatous and metastatic SCCA nodes. Descriptive statistics was used to evaluate lymph node diameter. Results Study population There was a total of 129 cervical nodes from 55 patients. The number of lymphomatous, metastatic SCCA, and normal cervical nodes was 50, 41, and 38, respectively. Baseline demographic, lymph node diameter, level of lymph nodes, and site of primary lesion of SCCA, including histopathologic subtypes of lymphoma, are described in Table 1 . Table 1. Clinical data of lymphomatous, metastatic SCCA and normal groups. Lymphoma Metastatic SCCA Normal Age (Mean±SD) 59.10±16.95 61.59±13.89 48.50±17.40 Gender 9 female 3 female 10 female 11 male 14 male 8 male Number of lymph nodes 50 41 38 Level of lymph nodes 1a (n=2) 1b (n=8) 2a (n=14) 2b (n=3) 3 (n=10) 4 (n=10) 5a (n=3) 5b (n=0) 6 (n=0) 1a (n=2) 1b (n=7) 2a (n=21) 2b (n=7) 3 (n=2) 4 (n=1) 5a (n=0) 5b (n=0) 6 (n=1) 1a (n=1) 1b (n=13) 2a (n=19) 2b (n=2) 3 (n=2) 4 (n=0) 5a (n=1) 5b (n=0) 6 (n=0) Average diameter of lymph nodes 14.16 (10.15-17.63) 10.64 (9.55-19.10) 5.82 (5.41-6.32) Note Histologic subtypes - Hodgkin lymphoma (n=6) - Non Hodgkin lymphoma (n=38) - Diffuse large B cell (n=10) - Follicular cell (n=12) - NLPHL (n=2) - T cell (n=8) - Marginal zone (n=3) - Round cell (n=3) Site of primary CA - Nasopharynx (n=11) - Nasal septum (n=2) - Tongue (n=3) - Floor of mouth (n=6) - Gum (n=5) - Retromolar trigone (n=2) - Tonsil (n=2) - Pyriform sinus (n=3) - Supraglottis (n=7) - Iodine density (ID) and contrast-enhanced attenuation value (CEAV) The mean (±SD) ID and CEAV of lymphomatous, metastatic SCCA, and normal cervical nodes are summarized in Table 2 and Figure 4 . There were significant differences of ID (p<0.001) and CEAV (p<0.001) between the three groups. Table 2. Comparison of parameters between lymphomatous, metastatic SCCA and normal nodes. Patient group Lymphoma SCCA Normal p-value ID of lymph nodes (mg/ml) 1.01±0.27 1.36±0.28 1.45±0.29 <0.001 * ID of SCM (mg/ml) 0.45±0.19 0.44±0.24 0.42±0.18 0.928 ID of IJV (mg/ml) 3.67±0.76 3.30±0.62 3.25±0.72 0.140 CEAV of lymph nodes (HU) 72.91±10.69 86.84±8.95 95.90±9.67 <0.001 * CEAV of SCM (HU) 68.27±7.31 67.27±9.74 68.27±5.51 0.848 CEAV of IJV (HU) 150.94±23.56 144.38±19.61 149.58±20.10 0.635 * Statistically significant at p-value<0.05 determined by One-way ANOVA. Figure 4. Box and whiskers plots of ID (A) & CEAV (B) of lymphoma, metastatic SCCA and normal nodes. Subgroup analysis showed that the ID of lymphomatous nodes (1.01±0.27 mg/ml) was significantly lower than the ID of metastatic SCCA (1.36±0.28 mg/ml), p=0.002, and it was also lower than the ID of normal nodes (1.45±0.29 mg/ml), p<0.0001. CEAV of lymphomatous nodes (72.91±10.69 HU) was significantly lower than the CEAV of metastatic SCCA (86.84±8.95 HU), p<0.0001, and it was lower than the CEAV of normal nodes (95.90±9.67 HU), p<0.0001. Comparative results of ID and CEAV between subgroups are summarized in Table 3 . Table 3. Pairwise comparison of iodine density and contrast enhanced attenuation value between each group. Mean difference Std. Error p-value ID Normal – Lymphoma 0.44 0.09 <0.001 * Normal – SCCA 0.09 0.09 0.640 Lymphoma – SCCA -0.35 0.09 0.002 * CEAV Normal – Lymphoma 22.98 3.20 <0.001 * Normal – SCCA 9.06 3.33 0.032 * Lymphoma – SCCA -13.93 3.25 <0.001 * * Statistically significant at p-value<0.05 determined by post-hoc test (Scheffe). There was no significant difference in ID or CEAV of the internal jugular vein (IJV) or sternocleidomastoid muscles (SCM) between the three groups, p≥0.05 ( Table 2 ). Receiver operating characteristic curve The ROC curve for ID and CEAV in differentiation between lymphoma and SCCA showed good diagnostic performance with the area under the curve at 0.788 (95% CI=0.632-0.944) and 0.851 (95% CI=0.721-0.982), respectively ( Figure 5 ). Figure 5. ROC curves for ID and CEAV as test to diagnose lymphomatous or metastatic SCCA nodes. Both curves show high diagnostic performance. The optimal cut-off value of ID to differentiate lymphomatous nodes from metastatic SCCA, as derived from the ROC curve, was 1.175 mg/ml with a sensitivity of 85% and specificity of 87.5 %. The CEAV at 77.5 HU could also differentiate between these entities, with a specificity of 88.9% and a sensitivity of 78.9%. Discussion This is the first study to use DLSCT to compare ID between lymphomatous, metastatic SCCA, and normal cervical lymph nodes. We found lymphomatous nodes had significantly lower ID and CEAV than metastatic SCCA and normal nodes. Our data suggested that a cut-off value of ID at 1.175 mg/ml may enable discrimination between lymphomatous and SCCA nodes with specificity of 84.2% and sensitivity of 77.8%. Some literature reported ID of cervical nodes studied on dual-sources or rapid-switch technique DECT. Prior studies rated ID and CEAV highest in normal nodes, followed by metastatic and then lymphomatous nodes, similar to our findings. 2 , 11 , 12 A study by Yang et al. also found lower ID of lymphomatous nodes than of metastatic SCCA nodes, but they did not show a statistical difference between these two diseases. 2 They performed the study using a rapid switch kVp machine (Gemstone spectral imaging) with acquisition time at 30 seconds after contrast administration, which might explain why their results differ from ours. The results from this study differ from results of previous studies performed in the abdominal area, which showed higher ID in lymphomatous nodes than in metastatic nodes. 13 Many studies demonstrated different IDs among various types of tumors. 14 – 16 Differences of histopathological types and vascular supply between neck and abdominal structures could explain these different ID results. Our results showed a lower ID of metastatic SCCA nodes than of normal neck nodes, which was similar to prior studies. 17 – 19 This might relate to HU distribution, which is highest at the center of normal nodes, whereas it is evenly distributed in metastatic nodes. 20 As normal nodes must be less than 8 mm in diameter, the ROI for ID measurement was inevitably placed at their center, resulting in a relatively higher ID. Greater vessel density in normal nodes than in metastatic lymph nodes with possible micronecrosis might explain this result. 19 , 21 The ID of metastatic SCCA nodes in this study (1.36±0.28 mg/ml) was lower than the ID in a study by Tawfik et al. (2.34±0.45 mg/ml) but higher than in the studies reported by Foust et al. (0.96±0.28 mg/ml) and Luo et al. (0.98±0.42 mg/ml). 17 , 19 , 22 Their studies were performed by dual-source DECT (Somatom; Siemens Healthcare, Erlangen, Germany) with different iodine concentrations of contrast media (350-400 iodine/ml). These could result in different ID values of the cervical lymph nodes with the same pathologic type. This study also showed a relatively lower ID in normal nodes (1.45±0.29 mg/ml) compared to a prior result from Sauter AP et al. (2.09±0.09 mg/ml), which also used a DLSCT machine (iQon, Philips Healthcare, Cleveland, OH, USA). 23 In contrast to this study, they used a higher iodine concentration of contrast media (Imeron 400) with a larger contrast volume (150 ml) on their CT neck protocol. These resulted in higher total iodine load and could have caused the higher ID values in their study. We also compared the CEAV of lymph nodes between each group. This approach is more practical for routine interpretation because it can be directly measured on PACS. The results corresponded to the ID results, with lowest values in lymphomatous, metastatic SCCA, and normal nodes, respectively. CEAV was notably significantly different between the three groups (p-value<0.001). As bolus tracking was not included in our routine CT neck protocol, we measured ID and CEAV of the sternocleidomastoid muscle (SCM) and internal jugular vein (IJV) to compare iodine content among the three groups. The results showed no significant difference in ID and CEAV of these two structures between the three patient groups (p-value>0.05). This study has several limitations. First, it was conducted retrospectively with small patient groups. Iodine qualification data were unavailable for some patients because they were referred to our health care center after having undergone conventional CT. Second, we did not compare ID and CEAV between each lymph node level because some nodes were too small, and we did not have nodes in levels III-VI in the normal group. Comparison between normal and diseased nodes in these cervical levels might affect the results. A larger-scale study including each cervical level might address this limitation. Third, considering prior studies which showed different ID between different types of tumors, 14 – 16 we hypothesized that ID might be affected by the histologic subtype of lymphoma. Study of ID in various lymphomatous subtypes might improve subtype differentiation. Fourth, not all lymph nodes in the lymphomatous group were confirmed because lymph node dissection was not standard treatment for this disease. Fifth, the ROI placement in this study was performed by a single reader, which precludes the evaluation of inter-reader variability. However, efforts were made to standardize the process and ensure consistency throughout the analysis. Incorporating multiple readers in future studies could provide additional insights into the reproducibility and reliability of the findings. Conclusion The results of our study indicate that ID and CEAV findings from DLSCT differed significantly between lymphomatous, metastatic SCCA, and normal cervical nodes. This knowledge improves differentiation of these conditions. Statements and declarations Ethical approval and consent to participate The Human Research Ethics Committee of Thammasat Univerity (Medicine) approved conducting this research with the certificate project number MTU-EC-RA-0-222/66, and approved on December 20, 2023. The inform-consent was waived requirement due to the retrospective nature of the study. Author contributions MV made contributions in literatures search, study design, data interpretation, draft writing, critical revision and final approval of the final version for submitted. WU made contributions in literatures search, data collection, data analysis and interpretation, and TW and WA made contributions in draft writing, critical revision and also faculty collaborations. Data availability Underlying data Zenodo: Iodine density of lymphoma, metastatic SCCA, and normal cervical lymph nodes: Based on DLSCT. https://doi.org/10.5281/zenodo.11120918 . 24 This project contains the following underlying data: Patients demographic data, iodine density and contrast attenuation value of neck nodes for Final data_18 Mar 2024_Final.xlsx . Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Extended data Reporting guidlines Zenodo: STARD checklist. https://doi.org/10.5281/zenodo.11120918 . 24 Acknowledgement We want to thank Assoc. Prof. Dr. Amonpon Kanlerd, Faculty of Medicine, Thammasat University, for helping us with language editing and submitting this manuscript. References 1. Chong V: Cervical lymphadenopathy: what radiologists need to know. Cancer Imaging. 2004; 4 (2): 116–120. PubMed Abstract | Publisher Full Text | Free Full Text 2. Yang L, Luo D, Li L, et al. : Differentiation of malignant cervical lymphadenopathy by dual-energy CT: a preliminary analysis. Sci. Rep. 2016; 6 (1): 31020. PubMed Abstract | Publisher Full Text | Free Full Text 3. Roland N, Bradley PJ: Neck swellings. BMJ. 2014; 348 . Publisher Full Text 4. Naeimi M, Sharifi A, Erfanian Y, et al. : Differential diagnosis of cervical malignant lymphadenopathy among Iranian patients. Saudi Med. J. 2009; 30 (3): 377–381. PubMed Abstract 5. Forghani R, Yu E, Levental M, et al. : Imaging evaluation of lymphadenopathy and patterns of lymph node spread in head and neck cancer. Expert. Rev. Anticancer. Ther. 2015; 15 (2): 207–224. PubMed Abstract | Publisher Full Text 6. Chan JM, Shin LK, Jeffrey RB: Ultrasonography of abnormal neck lymph nodes. Ultrasound Q. 2007; 23 (1): 47–54. Publisher Full Text 7. Qin Y, Lu L, Lu Y, et al. : Hodgkin lymphoma involving the tonsil misdiagnosed as tonsillar carcinoma: A case report and review of the literature. Medicine. 2018; 97 (7): e9761. PubMed Abstract | Publisher Full Text | Free Full Text 8. Cho K-S, Kang D-W, Kim H-J, et al. : Differential diagnosis of primary nasopharyngeal lymphoma and nasopharyngeal carcinoma focusing on CT, MRI, and PET/CT. Otolaryngol. Head Neck Surg. 2012; 146 (4): 574–578. PubMed Abstract | Publisher Full Text 9. Forghani R, De Man B, Gupta R: Dual-energy computed tomography: physical principles, approaches to scanning, usage, and implementation: part 1. Neuroimaging Clin. 2017; 27 (3): 371–384. Publisher Full Text 10. Forghani R, Mukherji S: Advanced dual-energy CT applications for the evaluation of the soft tissues of the neck. Clin. Radiol. 2018; 73 (1): 70–80. PubMed Abstract | Publisher Full Text 11. Hagtvedt T, Aaløkken T, Stensvold A, et al. : Computed tomography enhancement characteristics of lymphomatous lymph nodes of the neck. Dentomaxillofac. Radiol. 2007; 36 (4): 234–236. PubMed Abstract | Publisher Full Text 12. Hagtvedt T, Aaløkken TM, Smith H-J, et al. : Enhancement characteristics of lymphomatous lymph nodes of the neck. Acta Radiol. 2010; 51 (5): 555–562. PubMed Abstract | Publisher Full Text 13. Martin SS, Czwikla R, Wichmann JL, et al. : Dual-energy CT-based iodine quantification to differentiate abdominal malignant lymphoma from lymph node metastasis. Eur. J. Radiol. 2018; 105 : 255–260. PubMed Abstract | Publisher Full Text 14. Mileto A, Marin D, Alfaro-Cordoba M, et al. : Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study. Radiology. 2014; 273 (3): 813–820. Publisher Full Text 15. Martin SS, Weidinger S, Czwikla R, et al. : Iodine and fat quantification for differentiation of adrenal gland adenomas from metastases using third-generation dual-source dual-energy computed tomography. Investig. Radiol. 2018; 53 (3): 173–178. PubMed Abstract | Publisher Full Text 16. Chang S, Hur J, Im DJ, et al. : Volume-based quantification using dual-energy computed tomography in the differentiation of thymic epithelial tumours: an initial experience. Eur. Radiol. 2017; 27 : 1992–2001. PubMed Abstract | Publisher Full Text 17. Tawfik AM, Razek AA, Kerl JM, et al. : Comparison of dual-energy CT-derived iodine content and iodine overlay of normal, inflammatory and metastatic squamous cell carcinoma cervical lymph nodes. Eur. Radiol. 2014; 24 (3): 574–580. PubMed Abstract | Publisher Full Text 18. Luo Y-H, Mei X-L, Liu Q-R, et al. : Diagnosing cervical lymph node metastasis in oral squamous cell carcinoma based on third-generation dual-source, dual-energy computed tomography. Eur. Radiol. 2023; 33 (1): 162–171. PubMed Abstract | Publisher Full Text 19. Foust AM, Ali RM, Nguyen XV, et al. : Dual-energy CT-derived iodine content and spectral attenuation analysis of metastatic versus nonmetastatic lymph nodes in squamous cell carcinoma of the oropharynx. Tomography. 2018; 4 (2): 66–71. PubMed Abstract | Publisher Full Text | Free Full Text 20. Rizzo S, Radice D, Femia M, et al. : Metastatic and non-metastatic lymph nodes: quantification and different distribution of iodine uptake assessed by dual-energy CT. Eur. Radiol. 2018; 28 : 760–769. PubMed Abstract | Publisher Full Text 21. Naresh K, Nerurkar A, Borges A: Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology. 2001; 38 (5): 466–470. PubMed Abstract | Publisher Full Text 22. Luo Y-H, Mei X-L, Liu Q-R, et al. : Diagnosing cervical lymph node metastasis in oral squamous cell carcinoma based on third-generation dual-source, dual-energy computed tomography. Eur. Radiol. 2022; 33 : 162–171. Publisher Full Text 23. Sauter AP, Ostmeier S, Nadjiri J, et al. : Iodine concentration of healthy lymph nodes of neck, axilla, and groin in dual-energy computed tomography. Acta Radiol. 2020; 61 (11): 1505–1511. PubMed Abstract | Publisher Full Text 24. Mingkwansook V: Iodine density and contrast enhanced attenuation value of neck nodes. Zenodo. 2024. Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 17 May 2024 ADD YOUR COMMENT Comment Author details Author details 1 Radiology, Thammasat University, meung, pathumtani, 12000, Thailand Varalee Mingkwansook Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Urusaya Wangprasertkul Roles: Data Curation, Project Administration Warit Tarathipmon Roles: Formal Analysis Arvemas Watcharakorn Roles: Methodology Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (2) version 2 Revised Published: 02 Jan 2025, 13:498 https://doi.org/10.12688/f1000research.146149.2 version 1 Published: 17 May 2024, 13:498 https://doi.org/10.12688/f1000research.146149.1 Copyright © 2025 Mingkwansook V et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Mingkwansook V, Wangprasertkul U, Tarathipmon W and Watcharakorn A. Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.12688/f1000research.146149.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 02 Jan 2025 Revised Views 0 Cite How to cite this report: Piyapittayanan S. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.176267.r355399 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v2#referee-response-355399 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 15 Jan 2025 Siriwan Piyapittayanan , Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Approved VIEWS 0 https://doi.org/10.5256/f1000research.176267.r355399 No ... Continue reading READ ALL No new commment Competing Interests: No competing interests were disclosed. Reviewer Expertise: Neuroradiology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Piyapittayanan S. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.176267.r355399 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v2#referee-response-355399 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Intrapiromkul J. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.176267.r355400 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v2#referee-response-355400 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 03 Jan 2025 Jarunee Intrapiromkul , Neuroradiology Radiology, Nuclear Medicine, Pediatric Radiology, West Virginia University, Johns Hopkins University, Morgantown, Baltimore, USA Approved VIEWS 0 https://doi.org/10.5256/f1000research.176267.r355400 No ... Continue reading READ ALL No additional comment. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Head and neck imaging, perfusion imaging I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Intrapiromkul J. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.176267.r355400 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v2#referee-response-355400 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 17 May 2024 Views 0 Cite How to cite this report: Piyapittayanan S. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.160196.r344815 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v1#referee-response-344815 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 20 Dec 2024 Siriwan Piyapittayanan , Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Approved VIEWS 0 https://doi.org/10.5256/f1000research.160196.r344815 Comments 1. Study design; generally, metastatic cervical lymph nodes are not only SCCA. This study has not include another cell type of metastatic lymph node such as thyroid carcinoma, salivary gland carcinoma or metastatic node from organ outside head and ... Continue reading READ ALL Comments 1. Study design; generally, metastatic cervical lymph nodes are not only SCCA. This study has not include another cell type of metastatic lymph node such as thyroid carcinoma, salivary gland carcinoma or metastatic node from organ outside head and neck such as breast and lung cancer. Explain the reason that why this study include only SCCA nodal metastasis. 2. Heading; may put some word in the heading such as comparative, can iodine density differentiate between, to increasingly interest. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Neuroradiology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Piyapittayanan S. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.160196.r344815 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v1#referee-response-344815 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 23 Dec 2024 Varalee Mingkwansook , Radiology, Thammasat University, meung, 12000, Thailand 23 Dec 2024 Author Response Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA ... Continue reading Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA is one of the most common causes of metastatic cervical lymphadenopathy, particularly in head and neck cancers. By concentrating on SCCA, we aimed to investigate its specific iodine density patterns in relation to lymphoma. Including other types of metastatic lymph nodes, such as those from thyroid carcinoma, salivary gland carcinoma, or cancers from distant organs like the breast or lung, would introduce significant variability due to differences in tumor biology, vascularity, and iodine uptake. This variability could complicate the analysis and make it difficult to draw clear comparisons between the two malignancies. Focusing on SCCA allowed for a more homogenous study sample, providing clearer insights into iodine density patterns specific to SCCA and lymphoma, which is the primary goal of this research. We plan to explore a broader comparison in future studies. 2. The heading will be modified to "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical Lymph Nodes: A Comparative Analysis Using DLSCT" Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA is one of the most common causes of metastatic cervical lymphadenopathy, particularly in head and neck cancers. By concentrating on SCCA, we aimed to investigate its specific iodine density patterns in relation to lymphoma. Including other types of metastatic lymph nodes, such as those from thyroid carcinoma, salivary gland carcinoma, or cancers from distant organs like the breast or lung, would introduce significant variability due to differences in tumor biology, vascularity, and iodine uptake. This variability could complicate the analysis and make it difficult to draw clear comparisons between the two malignancies. Focusing on SCCA allowed for a more homogenous study sample, providing clearer insights into iodine density patterns specific to SCCA and lymphoma, which is the primary goal of this research. We plan to explore a broader comparison in future studies. 2. The heading will be modified to "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical Lymph Nodes: A Comparative Analysis Using DLSCT" Competing Interests: The authors declare no competing interests Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 23 Dec 2024 Varalee Mingkwansook , Radiology, Thammasat University, meung, 12000, Thailand 23 Dec 2024 Author Response Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA ... Continue reading Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA is one of the most common causes of metastatic cervical lymphadenopathy, particularly in head and neck cancers. By concentrating on SCCA, we aimed to investigate its specific iodine density patterns in relation to lymphoma. Including other types of metastatic lymph nodes, such as those from thyroid carcinoma, salivary gland carcinoma, or cancers from distant organs like the breast or lung, would introduce significant variability due to differences in tumor biology, vascularity, and iodine uptake. This variability could complicate the analysis and make it difficult to draw clear comparisons between the two malignancies. Focusing on SCCA allowed for a more homogenous study sample, providing clearer insights into iodine density patterns specific to SCCA and lymphoma, which is the primary goal of this research. We plan to explore a broader comparison in future studies. 2. The heading will be modified to "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical Lymph Nodes: A Comparative Analysis Using DLSCT" Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA is one of the most common causes of metastatic cervical lymphadenopathy, particularly in head and neck cancers. By concentrating on SCCA, we aimed to investigate its specific iodine density patterns in relation to lymphoma. Including other types of metastatic lymph nodes, such as those from thyroid carcinoma, salivary gland carcinoma, or cancers from distant organs like the breast or lung, would introduce significant variability due to differences in tumor biology, vascularity, and iodine uptake. This variability could complicate the analysis and make it difficult to draw clear comparisons between the two malignancies. Focusing on SCCA allowed for a more homogenous study sample, providing clearer insights into iodine density patterns specific to SCCA and lymphoma, which is the primary goal of this research. We plan to explore a broader comparison in future studies. 2. The heading will be modified to "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical Lymph Nodes: A Comparative Analysis Using DLSCT" Competing Interests: The authors declare no competing interests Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Intrapiromkul J. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.160196.r282853 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v1#referee-response-282853 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 08 Aug 2024 Jarunee Intrapiromkul , Neuroradiology Radiology, Nuclear Medicine, Pediatric Radiology, West Virginia University, Johns Hopkins University, Morgantown, Baltimore, USA Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.160196.r282853 For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. Is the size of ROI the same in all cases? Is it placed on the solid portion? For lymph nodes with heterogeneous ... Continue reading READ ALL For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. Is the size of ROI the same in all cases? Is it placed on the solid portion? For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. The details of ROI placement should be described in more detail so that the study can be reproduce. Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Partly Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Head and neck imaging, perfusion imaging I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Intrapiromkul J. Reviewer Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.160196.r282853 ) The direct URL for this report is: https://f1000research.com/articles/13-498/v1#referee-response-282853 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 22 Aug 2024 Varalee Mingkwansook , Radiology, Thammasat University, meung, 12000, Thailand 22 Aug 2024 Author Response For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? ... Continue reading For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? - ROI placement for each lymph node was drawn in the largest area as much as possible in the solid portion. The size must be at least 6 mm 2 . - Is it placed on the solid portion? - Yes. ROIs were placed on the solid enhancing portion. Areas of necrosis, cyst, calcification or fat were carefully avoided. - For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. - If the solid portion (excluding necrosis, cystic area, fat and calcification) was heterogenously enhanced, we drawn the largest ROI as much as possible to acheive the reliable ROI. The mean HU of each ROI was used as a representative for each lymph node. - The details of ROI placement should be described in more detail so that the study can be reproduce. - ROIs were placed on axial images in which lymph nodes appeared the most prominent enhancement (3 nodes maximum). If the lymph node had similar degree of enhancement on each axial view, the slice which lymph node appeared to be largest was selected in order to achieve the largest ROI. ROI must be at least 6 mm 2 in size. We drew largest ROI for each lymph node as much as possible, avoiding areas of necrosis, cyst, calcification or fat. - Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. - We will conduct the new article with more subjects and providing inter-reader variability in the future. - The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers - The authors agree with this issue which already mentioned in discussion section. For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? - ROI placement for each lymph node was drawn in the largest area as much as possible in the solid portion. The size must be at least 6 mm 2 . - Is it placed on the solid portion? - Yes. ROIs were placed on the solid enhancing portion. Areas of necrosis, cyst, calcification or fat were carefully avoided. - For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. - If the solid portion (excluding necrosis, cystic area, fat and calcification) was heterogenously enhanced, we drawn the largest ROI as much as possible to acheive the reliable ROI. The mean HU of each ROI was used as a representative for each lymph node. - The details of ROI placement should be described in more detail so that the study can be reproduce. - ROIs were placed on axial images in which lymph nodes appeared the most prominent enhancement (3 nodes maximum). If the lymph node had similar degree of enhancement on each axial view, the slice which lymph node appeared to be largest was selected in order to achieve the largest ROI. ROI must be at least 6 mm 2 in size. We drew largest ROI for each lymph node as much as possible, avoiding areas of necrosis, cyst, calcification or fat. - Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. - We will conduct the new article with more subjects and providing inter-reader variability in the future. - The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers - The authors agree with this issue which already mentioned in discussion section. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 22 Aug 2024 Varalee Mingkwansook , Radiology, Thammasat University, meung, 12000, Thailand 22 Aug 2024 Author Response For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? ... Continue reading For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? - ROI placement for each lymph node was drawn in the largest area as much as possible in the solid portion. The size must be at least 6 mm 2 . - Is it placed on the solid portion? - Yes. ROIs were placed on the solid enhancing portion. Areas of necrosis, cyst, calcification or fat were carefully avoided. - For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. - If the solid portion (excluding necrosis, cystic area, fat and calcification) was heterogenously enhanced, we drawn the largest ROI as much as possible to acheive the reliable ROI. The mean HU of each ROI was used as a representative for each lymph node. - The details of ROI placement should be described in more detail so that the study can be reproduce. - ROIs were placed on axial images in which lymph nodes appeared the most prominent enhancement (3 nodes maximum). If the lymph node had similar degree of enhancement on each axial view, the slice which lymph node appeared to be largest was selected in order to achieve the largest ROI. ROI must be at least 6 mm 2 in size. We drew largest ROI for each lymph node as much as possible, avoiding areas of necrosis, cyst, calcification or fat. - Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. - We will conduct the new article with more subjects and providing inter-reader variability in the future. - The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers - The authors agree with this issue which already mentioned in discussion section. For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? - ROI placement for each lymph node was drawn in the largest area as much as possible in the solid portion. The size must be at least 6 mm 2 . - Is it placed on the solid portion? - Yes. ROIs were placed on the solid enhancing portion. Areas of necrosis, cyst, calcification or fat were carefully avoided. - For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. - If the solid portion (excluding necrosis, cystic area, fat and calcification) was heterogenously enhanced, we drawn the largest ROI as much as possible to acheive the reliable ROI. The mean HU of each ROI was used as a representative for each lymph node. - The details of ROI placement should be described in more detail so that the study can be reproduce. - ROIs were placed on axial images in which lymph nodes appeared the most prominent enhancement (3 nodes maximum). If the lymph node had similar degree of enhancement on each axial view, the slice which lymph node appeared to be largest was selected in order to achieve the largest ROI. ROI must be at least 6 mm 2 in size. We drew largest ROI for each lymph node as much as possible, avoiding areas of necrosis, cyst, calcification or fat. - Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. - We will conduct the new article with more subjects and providing inter-reader variability in the future. - The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers - The authors agree with this issue which already mentioned in discussion section. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 17 May 2024 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 Version 2 (revision) 02 Jan 25 read read Version 1 17 May 24 read read Jarunee Intrapiromkul , West Virginia University, Johns Hopkins University, Morgantown, Baltimore, USA Siriwan Piyapittayanan , Siriraj Hospital, Mahidol University, Bangkok, Thailand Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Piyapittayanan S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 15 Jan 2025 | for Version 2 Siriwan Piyapittayanan , Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand 0 Views copyright © 2025 Piyapittayanan S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions No new commment Competing Interests No competing interests were disclosed. Reviewer Expertise Neuroradiology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Piyapittayanan S. Peer Review Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.176267.r355399) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-498/v2#referee-response-355399 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Intrapiromkul J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Jan 2025 | for Version 2 Jarunee Intrapiromkul , Neuroradiology Radiology, Nuclear Medicine, Pediatric Radiology, West Virginia University, Johns Hopkins University, Morgantown, Baltimore, USA 0 Views copyright © 2025 Intrapiromkul J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions No additional comment. Competing Interests No competing interests were disclosed. Reviewer Expertise Head and neck imaging, perfusion imaging I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Intrapiromkul J. Peer Review Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.176267.r355400) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-498/v2#referee-response-355400 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Piyapittayanan S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 20 Dec 2024 | for Version 1 Siriwan Piyapittayanan , Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand 0 Views copyright © 2024 Piyapittayanan S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Comments 1. Study design; generally, metastatic cervical lymph nodes are not only SCCA. This study has not include another cell type of metastatic lymph node such as thyroid carcinoma, salivary gland carcinoma or metastatic node from organ outside head and neck such as breast and lung cancer. Explain the reason that why this study include only SCCA nodal metastasis. 2. Heading; may put some word in the heading such as comparative, can iodine density differentiate between, to increasingly interest. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Neuroradiology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 23 Dec 2024 Varalee Mingkwansook, Radiology, Thammasat University, meung, 12000, Thailand Thank you for your valuable comment. 1. The decision to focus solely on metastatic SCCA in cervical lymph nodes was made to ensure a more controlled and focused analysis. SCCA is one of the most common causes of metastatic cervical lymphadenopathy, particularly in head and neck cancers. By concentrating on SCCA, we aimed to investigate its specific iodine density patterns in relation to lymphoma. Including other types of metastatic lymph nodes, such as those from thyroid carcinoma, salivary gland carcinoma, or cancers from distant organs like the breast or lung, would introduce significant variability due to differences in tumor biology, vascularity, and iodine uptake. This variability could complicate the analysis and make it difficult to draw clear comparisons between the two malignancies. Focusing on SCCA allowed for a more homogenous study sample, providing clearer insights into iodine density patterns specific to SCCA and lymphoma, which is the primary goal of this research. We plan to explore a broader comparison in future studies. 2. The heading will be modified to "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical Lymph Nodes: A Comparative Analysis Using DLSCT" View more View less Competing Interests The authors declare no competing interests reply Respond Report a concern Piyapittayanan S. Peer Review Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.160196.r344815) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-498/v1#referee-response-344815 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Intrapiromkul J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 08 Aug 2024 | for Version 1 Jarunee Intrapiromkul , Neuroradiology Radiology, Nuclear Medicine, Pediatric Radiology, West Virginia University, Johns Hopkins University, Morgantown, Baltimore, USA 0 Views copyright © 2024 Intrapiromkul J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. Is the size of ROI the same in all cases? Is it placed on the solid portion? For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. The details of ROI placement should be described in more detail so that the study can be reproduce. Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Partly Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Head and neck imaging, perfusion imaging I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 22 Aug 2024 Varalee Mingkwansook, Radiology, Thammasat University, meung, 12000, Thailand For ROI measurement, there is no clear description on how to place the ROI in the lymph nodes. - Is the size of ROI the same in all cases? - ROI placement for each lymph node was drawn in the largest area as much as possible in the solid portion. The size must be at least 6 mm 2 . - Is it placed on the solid portion? - Yes. ROIs were placed on the solid enhancing portion. Areas of necrosis, cyst, calcification or fat were carefully avoided. - For lymph nodes with heterogeneous enhancement, do you place it on the most enhanced portion or cover all lymph nodes. - If the solid portion (excluding necrosis, cystic area, fat and calcification) was heterogenously enhanced, we drawn the largest ROI as much as possible to acheive the reliable ROI. The mean HU of each ROI was used as a representative for each lymph node. - The details of ROI placement should be described in more detail so that the study can be reproduce. - ROIs were placed on axial images in which lymph nodes appeared the most prominent enhancement (3 nodes maximum). If the lymph node had similar degree of enhancement on each axial view, the slice which lymph node appeared to be largest was selected in order to achieve the largest ROI. ROI must be at least 6 mm 2 in size. We drew largest ROI for each lymph node as much as possible, avoiding areas of necrosis, cyst, calcification or fat. - Also, having a second reader placing the ROI is a great way to ensure the study reproducibility by evaluating the inter-reader variability. The mean value from 2 readers can then be used for analysis. - We will conduct the new article with more subjects and providing inter-reader variability in the future. - The proposed cut-off ID value may depend on the contrast concentration and dosage, which are varied on each imaging centers - The authors agree with this issue which already mentioned in discussion section. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Intrapiromkul J. Peer Review Report For: Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical lymph nodes: A Comparative Analysis Based on DLSCT [version 2; peer review: 2 approved] . F1000Research 2025, 13 :498 ( https://doi.org/10.5256/f1000research.160196.r282853) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-498/v1#referee-response-282853 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Iodine Density of Lymphoma, Metastatic SCCA,...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/13-498/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/13-498/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/13-498/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Mingkwansook V et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/13-498/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/13-498", templates : { twitter : "Iodine Density of Lymphoma, Metastatic SCCA, and Normal Cervical.... Mingkwansook V et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/13-498/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/146149/176267") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "176267"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "307972": 0, "288260": 0, "307973": 0, "288261": 0, "307974": 0, "288262": 0, "307968": 0, "288256": 0, "307969": 0, "288257": 0, "307970": 0, "288258": 0, "307971": 0, "288259": 0, "301340": 0, "301341": 0, "301342": 0, "301343": 0, "301338": 0, "301339": 0, "297124": 0, "297125": 0, "297126": 0, "297127": 0, "301344": 0, "301345": 0, "301346": 0, "297122": 0, "301347": 0, "297123": 0, "297128": 0, "297129": 0, "297130": 0, "297131": 0, "355399": 5, "333251": 0, "355400": 6, "282844": 0, "282845": 0, "282846": 0, "282847": 0, "282852": 0, "282853": 48, "282848": 0, "282849": 0, "282850": 0, "282851": 0, "313580": 0, "313581": 0, "344815": 10, "307965": 0, "288253": 0, "307966": 0, "288254": 0, "307967": 0, "288255": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "f9c43d5f-afc4-42ad-87a0-d1916f12b8cc"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });